Recurrent Melanoma Terminated Phase 1 / 2 Trials for Denileukin diftitox (DB00004)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00945269Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaTreatment